|
Synonyms: compound 1 [WO2020024977] | MT-200605
Compound class:
Synthetic organic
Comment: MT200605 is a small-molecule tropomyosin receptor kinase B (TrkB; NTRK2) agonist [2], that mimics the effect of endogenous agonist (brain-derived neurotrophic factor, BDNF)-mediated receptor activation and downstream signalling [1]. This mechanism is proposed for neuroprotective action, to inhibit ischaemic-reperfusion injury following cerebral stroke.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| MT200605 was progressed as a clinical candidate, with first-in-human phase 1 results published in September 2026 [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05948774 | A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects | Phase 1 Interventional | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | ||
| NCT07205328 | A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke | Phase 2 Interventional | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | ||